Incyte reported "strong" Q3 results as the Jakafi franchise continues its solid growth, Piper Jaffray analyst Tyler Van Buren tells investors in a post-earnings research note. The analyst say he's encouraged to hear that the initial Jakafi launch in refractory acute graft versus host disease has been outpacing internal expectations. These updates suggest that the $2.5B-$3.0B long-term Jakafi guidance by 2027 "will be easily achieved," Van Buren says. He sees long-term upside from current share levels and reiterates an Overweight rating on Incyte with a $95 price target.